Purpose-Since 1996, 16 states have legalized marijuana use for medical purposes. The current study provides a scientific assessment of the association of medical marijuana laws (MML) and adolescent marijuana use using national data.
Introduction
Between 1996 and 2011, 16 states passed laws legalizing use of marijuana for medical purposes when medically authorized [1] . Due to the potential for serious short-and longterm consequences of marijuana use in adolescence [2] [3] [4] [5] [6] [7] , prevention of adolescent marijuana initiation is a key NIDA strategy [8] . Although the potential impact of MML has been much discussed in the popular press, formal scientific assessments of the relation between MML and adolescent marijuana use using national data are lacking. Using 2002 Using -2008 data from the National Survey on Drug Use and Health (NSDUH), we compared the prevalence of marijuana use and perceptions of its riskiness among 12-17 year olds in states that have passed medical marijuana laws (MML) to states without such laws.
Methods
The NSDUH is administered to approximately 70,000 individuals annually and oversamples adolescents so that approximately one-third (n=23,300) of the sample includes 12 to 17 year olds. Publicly available state-level estimates for NSDUH respondents aged 12-17 were compiled from 2002-2008 with 2008 being the most current results presently available [9] . The NSDUH survey was initiated in 1999, but due to improvements in data collection procedures in 2002, prevalence rates before 2002 are not comparable and are thus not included [10] . State-level estimates are derived using a survey-weighted hierarchical Bayes estimation approach [10] aggregated over two-year intervals. We analyzed two NSDUH outcomes: (1) prevalence (percent) of past-month marijuana use and (2) percent responding that "great risk" is associated with smoking marijuana at least once a month.
First, we plotted and summarized the prevalence of past-month marijuana use by year and state and MML status (see footnote of Figure 1 ). Second, for each year, we performed 2sample t-tests comparing the outcomes in states which had passed MML by that year to states that had not passed MML by the same year. For example, we compared the prevalence of past-month use in 8 states with MML in 2002 to the remaining 42 states that had not passed MML by 2002. Third, we performed a longitudinal analysis including a random intercept for state and a fixed linear trend for year to compare the prevalence of marijuana use and perceived riskiness in the years prior to MML passage (data available for 8 states prior to MML) to that of: 1) post-MML years in states that passed MML and 2) all years for states that did not pass MML by 2011.
Results
The overall prevalence of past-month marijuana use among 12-17 year olds averaged across all states and years was 7.50%. Figure 1 shows the prevalence by year for each state. The 16 states which passed MML (thick lines; solid after passage and dashed before passage) by 2011 had higher average use, 8.68% (95% CI: 7.95-9.42%), during the period 2002-2008 compared to the 34 states without MML, 6.94% (95% CI: 6.60-7.28%). Two states without MML but with high average use were New Hampshire (9.50%) and Massachusetts (9.34%), which both had years with prevalence above 10%. Mean use in New Jersey (6.43%), Arizona (7.35%), and Delaware (7.58%) the three states to pass MML most recently, and California (7.30%) the first MML state in 1996, was on the lower end of states with MML.
In each year, the prevalence of marijuana use was significantly higher in states with MML, and perceived riskiness of marijuana use was significantly lower (Table 1) . Longitudinal analyses controlling for a statistically significant decreasing trend in marijuana use from 2002-2008 (β= −.35, t-value = −15.9, p-value <.0001) found that among the 8 states that passed MML since 2004, the prevalence of use in the years prior to passing laws was 8.88%, not significantly different (p=0.25) than states that had already passed laws (8.58%), but significantly higher than the prevalence for states without MML by 2011 (6.94%, p<.0001). Perceived riskiness of marijuana use in states in the years prior to passing MML was 30.5%, not significantly different than states that already passed laws (30.9%, p=0.58) but significantly lower than states without MML (35.7%, p<.0001).
Discussion
Between 2002 and 2008, adolescent marijuana use was higher and perception of its riskiness lower in states with medical marijuana laws compared to states without such laws. There are several possible explanations for this observation. First, it is possible that states with higher marijuana use and lower perceptions of risk are more likely to enact MML. This explanation is supported in the current analysis by the observation that among states that eventually enacted MML, use was higher and perceptions of risk lower even prior to passage of MML. Second, it is possible that MML causes changes in marijuana use and perceptions thereof. A longer time window of pre/post data would be needed to provide enough information both before and after passage of MML for each state to investigate this possibility. Third, it is possible that common factors drive both use and perceptions of risk and implementation of MML. For example, changing cultural norms around drug use may influence both. Given the fast-changing nature of medical marijuana laws and the fact that most claims about its association with adolescent marijuana use are based on opinion, the current study provides needed information describing the relationship and suggests the clear need for more empirically-based research on this topic. 2 Massachusettes MA and New Hampshire NH are labeled because of their high prevalence among states without MML Table 1 Yearly comparison of prevalence of marijuana use within the past month and perception of riskiness of marijuana for 12-17 year olds in states having already passed a medical marijuana law (MML) to those without MML in that year. 
